Company profile: Altor BioScience
1.1 - Company Overview
Company description
- Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
Products and services
- ANKTIVA (N-803): IL-15 receptor agonist biologic that activates natural killer and T cells to attack tumor cells, used to treat non-muscle invasive bladder cancer
- Investigational Cancer Therapies and Vaccines: Custom-engineered immunotherapeutic products harness innate and adaptive immunity to target cancer, including personalized vaccines based on neoepitope prediction
- Tri-Ad5 Vaccine Combination: Multi-antigen assembly combining three vaccines against distinct cancer-associated proteins, studied for preventing colorectal and other cancers in Lynch syndrome patients through prophylactic immunization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Altor BioScience
AM-Pharma
HQ: The Netherlands
Website
- Description: Provider of biopharmaceutical therapeutics focused on inflammatory and infectious diseases, developing and commercializing products based on endogenous proteins, including ilofotase alfa, a recombinant alkaline phosphatase under development to prevent cardiac surgery-associated renal damage and as enzyme replacement therapy for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AM-Pharma company profile →
VivaBioCell
HQ: Italy
Website
- Description: Provider of innovative products leveraging proprietary cell culture and tissue engineering technologies for early diagnosis of autoimmune diseases (e.g., scleroderma, graft-versus-host disease) and treatment of oro-dental and maxillo-facial defects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VivaBioCell company profile →
Paloma Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage drug development focusing on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway, including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (renal and pulmonary fibrosis), and CNS (epilepsy and neurodegenerative).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paloma Pharmaceuticals company profile →
Harbor Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary class of adrenal steroid hormones developed as novel pharmaceuticals and potential nutraceuticals for human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbor Therapeutics company profile →
Cumberland Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical offerings focused on acquiring, developing, and commercializing branded prescription products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cumberland Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Altor BioScience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Altor BioScience
2.2 - Growth funds investing in similar companies to Altor BioScience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Altor BioScience
4.2 - Public trading comparable groups for Altor BioScience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →